155 results about "Etoposide" patented technology

The present invention provides oral dosage forms and compositions for administering antineoplastic agents, such as irinotecan, etoposide, paclitaxel, doxorubicin and vincristine, whose oral effectiveness is limited by pre-systemic and systemic deactivation in the GI tract. Gelling of the gastric retention vehicle composition, and in the case of solid forms concomitant expansion of the composition, retains the antineoplastic drug in the patient's stomach, minimizing pre-systemic and / or systemic deactivation of the drug.

Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

The present invention provides an inhalation-type pharmaceutical composition for lung cancer and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising cisplatin, docetaxel, etoposide, gefitinib, erlotinib, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Provided herein are methods for predicting the responsiveness of a cancer to a chemotherapeutic agent using gene expression profiles. In particular, methods for predicting the responsiveness to 5-fluorouracil, adriamycin, cytotoxan, docetaxol, etoposide, taxol, topotecan, PB kinase inhibitors and Src inhibitors are provided. Methods for developing treatment plans for individuals with cancer are also provided. Kits including gene chips and instructions for predicting responsiveness and computer readable media comprising responsivity information are also provided.

The invention relates to an etoposide lyophilized powder for injection. The powder can overcome the defects of etoposide, improve the bioavailability of etoposide, is convenient to use, can be absorbed fast, and can come into play rapidly. By screening the prescription of the etoposide lyophilized powder for injection, the invention finds that the combined use of a specific excipient with an antioxidant and a chelating agent at the same time can generate a finished product of etoposide lyophilized powder for injection with the advantages of high stability, fewer impurities, little side effect, high safety, convenient storage and use, low production cost, and the like.

The invention discloses dehydroabietic acid benzimidazole Schiff base heterocyclic derivatives with anti-tumor activity and a preparation method therefor and an application thereof. The invention discloses a dehydroabietic acid benzimidazole Schiff base heterocyclic derivative which has a structure shown in a formula I and pharmaceutically acceptable salt thereof (the formula is shown in the description), wherein the formula is shown in the description. The dehydroabietic acid benzimidazole Schiff base heterocyclic derivative and the pharmaceutically acceptable salt thereof have remarkable anti-tumor activity. Pharmacological experiments show that the dehydroabietic acid benzimidazole Schiff base heterocyclic derivatives have remarkable inhibitory effect on human liver cancer cells HepG2 and SMMC-7721 and the effect of the derivatives is equivalent to positive control etoposide. The derivatives and salt thereof have the potential of developing anti-tumor drugs.

The present invention belongs to the field of medicine technology, and is especially lipoid microsphere injection containing etoposide and its preparation process. The injection contains etoposide, fat soluble medium, water and surfactant; and consists of oil phase 5-30 wt%, etoposide 0.001-0.5 wt%, surfactant 0.5-5 wt%, osmotic regulator 0.5-5 wt%, and water for injection the rest. Etoposide is high pressure homogenized under the action of high speed airflow to form ultrasonic stirring, so as to be dissolved fast and permeated in molecular form into oil / water interface film. By means of medicine carrying interface film principle, the present invention raises the medicine carrying amount of insoluble etoposide and the stability while lowering the toxicity and blood vessel irritation. The preparation of the present invention has low toxicity, low irritation and high curative effect in clinical application.

Anthracyclines-treated tumor cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclines induce the rapid, pre-apoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knock down of CRT suppressed the phagocytosis of anthracyclines-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. The anthracyclines-induced CRT translocation was mimicked by inhibition of the protein phosphatase1 / GADD34 complex. Administration of recombinant CRT or inhibitors of protein phosphatase1 / GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify CRT as a key feature determining anti-cancer immune responses and delineate a possible strategy for immunogenic chemotherapy.

The invention belongs to the technical field of medicines and in particular relates to an etoposide cubic liquid crystal as well as a preparation method and application thereof. The preparation method comprises the following steps: firstly selecting a lipid material / water system and a stabilizer for preparing the etoposide cubic liquid crystal, wherein the average particle size of the prepared etoposide cubic liquid crystal is 208nm, and the encapsulation efficiency is 60-65%; and secondly preparing the etoposide cubic liquid crystal into a hollow suppository by adopting a special pharmaceutical adjuvant combination, so that drug bioavailability and drug stability are improved, toxic and side effects are reduced, and targeted drug delivery is realized; and a preparation process is simple, instruments are available, and the preparation time is short.

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and / or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and / or compounds from the implantable medical devices.